Clinical Trial Update: Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung [Phase 2]

View source ↗

Summary

Phase 2 study evaluating REOLYSIN (pelareorep) for bone and soft tissue sarcomas metastatic to the lung has been completed, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Fibrosarcoma
• Leiomyosarcoma
• Osteosarcoma
• Synovial Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• REOLYSIN (pelareorep)

Snippet

Sponsor: Oncolytics Biotech | Conditions: Osteosarcoma, Ewing Sarcoma Family Tumors | Phase 2 | Status: COMPLETED